Ab Initio: Ab Initio and Pfizer partner to discover GPCR activating antibodies
US-based Ab Initio Biotherapeutics and Pfizer have signed a research and licence agreement to discover novel therapeutic antibodies against an undisclosed target in the G-protein coupled receptor (GPCR) superfamily.
Read full article »
Founder & CEO
Sheryl Handler
Ab Initio is an enterprise software firm that specializes in data processing applications and enterprise application integration.
Read more